TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23945570

Group type: EXPERIMENTAL
Intervention: Intramuscular gentamicin once daily and oral amoxicillin twice daily for 7 days
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin and gentamicin once daily for 2 days followed by oral amoxicillin twice daily for additional 5 days
Number of subjects: 750

Group type: COMPARATOR
Intervention: Intramuscular procaine-benzyl penicillin and gentamicin given once daily for 7 days
Number of subjects: 750
Study: 21149658

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Radical Prostatectomy (RP)
Number of subjects: 168
Study: 18272932

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking at 60% of maximal oxygen uptake for 90 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 12
Study: 16517034

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hib (Group 1)
Number of subjects: 241

Group type: COMPARATOR
Intervention: DTwP/Hib+OPV (Group 2)
Number of subjects: 241
Study: 14504951

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance measured at 50 kHz using Multiscan-5000 device.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue layers (SAT-layers) measured by LIPOMETER at various body sites.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Skinfold thicknesses measured by caliper.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Iliac crest and front thigh skinfold thicknesses measured by caliper.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lateral thigh SAT-layer.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sum of skinfolds or SAT-layers.
Number of subjects: 96
Study: 10744590

Group type: EXPERIMENTAL
Intervention: Walnut diet (replacing approximately 35% of energy from monounsaturated fat)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 55
Study: 9095609

Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.02 microgram.kg‐1.min‐1 before induction of anesthesia
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 109
Study: 8240151

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg daily, titrated to 40 mg daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pravastatin 10 mg daily, titrated to 40 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simvastatin (after switching from pravastatin)
Number of subjects: 48
Study: 3549809

Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29099727

Group type: EXPERIMENTAL
Intervention: Supplemental computational phantoms and dose‐calculation models
Number of subjects: 9
Study: 26923704

Group type: EXPERIMENTAL
Intervention: Erythrocyte linoleic acid (LA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Erythrocyte oleic acid (OA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Erythrocyte long chain omega-3 fatty acids (LC-Ω3-SUM)
Number of subjects: 139
Study: 24729041

Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m²/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22951490

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg once daily
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once daily
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V90I mutation
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V90I mutation
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V106I mutation
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V106I mutation
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V179I mutation
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V179I mutation
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V189I mutation
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V189I mutation
Number of subjects: 1796
Study: 21049089

Group type: EXPERIMENTAL
Intervention: Olanzapine 5-20 mg/day
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Haloperidol 2-20 mg/day
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Risperidone 2-10 mg/day
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Ziprasidone 80-160 mg/day
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1062
Study: 18284439

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with venlafaxine for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with venlafaxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 16024406

Group type: EXPERIMENTAL
Intervention: Experimental program 'Taking Care of Myself' (EG)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Comparison program offered by an Alzheimer Society (AG)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 137
Study: 12529349

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day, N = 2700
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo, N = 2708
Number of subjects: 5408

Group type: EXPERIMENTAL
Intervention: Tamoxifen, high-risk group
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo, high-risk group
Number of subjects: 5408

Group type: EXPERIMENTAL
Intervention: Tamoxifen, low-risk group
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo, low-risk group
Number of subjects: 5408

Group type: EXPERIMENTAL
Intervention: Tamoxifen, ER+ tumors, high-risk group
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo, ER+ tumors, high-risk group
Number of subjects: 5408
Study: 10541421

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 880 microg/day
Number of subjects: 30
Study: 8759815

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1806734

Group type: EXPERIMENTAL
Intervention: 650 mg of ASA
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6859372

Group type: EXPERIMENTAL
Intervention: Preoperative serum antisperm antibody titer of 512 or more
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Preoperative serum antisperm antibody titer below 512
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Presence of seminal plasma antibodies (titers up to 16)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Perioperative steroids (randomized controlled trial)
Number of subjects: 130
Study: 31192254

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Forns
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: GAPRI
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Hepascore
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Age-Platelet
Number of subjects: 142
Study: 29105045

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard weight-control programme
Number of subjects: 60
Study: 27189190

Group type: EXPERIMENTAL
Intervention: Podiatry treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Potassium hydroxide (KOH, 40%)
Number of subjects: 46
Study: 24475111

Group type: EXPERIMENTAL
Intervention: 110% relative to the resting motor threshold (rMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 120% relative to the resting motor threshold (rMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both stimulation intensities (110% rMT and 120% rMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher rMT subjects
Number of subjects: 36
Study: 21960086

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19913984

Group type: EXPERIMENTAL
Intervention: Training with manikin-DVD set facilitated by high school students
Number of subjects: 4

Group type: COMPARATOR
Intervention: Pre-training
Number of subjects: 4
Study: 17625280

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy and magnification endoscopy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 15
Study: 16311460

Group type: EXPERIMENTAL
Intervention: New apparatus for performing infusion tests in a standardized and automated way
Number of subjects: 14
Study: 12372312

Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-tape condition
Number of subjects: 20
Study: 9706941

Group type: EXPERIMENTAL
Intervention: ETCO2 of 25 mm Hg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ETCO2 of 45 mm Hg
Number of subjects: 7
Study: 7705113

Group type: EXPERIMENTAL
Intervention: Specific Inspiratory Muscle Training (SIMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 12
Study: 2612300

Group type: COMPARATOR
Intervention: 25 mg ALEC powder
Number of subjects: 459

Group type: COMPARATOR
Intervention: 1 ml of 100 mg ALEC suspension
Number of subjects: 459

Group type: COMPARATOR
Intervention: ALEC treatment
Number of subjects: 459
Study: 619513

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 0
Study: 31556975

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 27317843

Group type: EXPERIMENTAL
Intervention: Baseline IGFBP7 (BL-IGFBP7)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 6-month change in IGFBP7 (ΔIGFBP7) in patients randomized to irbesartan
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: IGFBP7 concentrations
Number of subjects: 302
Study: 26244854

Group type: EXPERIMENTAL
Intervention: Telephone-delivered Cognitive Behavioral Therapy (CBT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Telephone-delivered Nondirective Supportive Therapy (NST)
Number of subjects: 141
Study: 23555980

Group type: EXPERIMENTAL
Intervention: Antimalarials plus antibiotics
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Antimalarials only (intervention arm)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Antimalarials only (control arm)
Number of subjects: 667
Study: 22451889

Group type: EXPERIMENTAL
Intervention: Epithalamin (peptide drug), 6 courses over 3 years
Number of subjects: 79

Group type: COMPARATOR
Intervention: Basic therapy alone (Control)
Number of subjects: 79
Study: 19781465

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% drops 4 times a day for 1 day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Topical moxifloxacin 0.5% drops 4 times a day for 3 days
Number of subjects: 120
Study: 16400044

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg Ca/d as calcium carbonate)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 15302007

Group type: EXPERIMENTAL
Intervention: Low-sodium diet for 15 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 24
Study: 11406341

Group type: COMPARATOR
Intervention: Basal intravenous infusion of saline solution with verbal instructions of a powerful painkiller (double-blind administration)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Basal intravenous infusion of saline solution with verbal instructions of a potent painkiller (deceptive administration)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Basal intravenous infusion of saline solution with no verbal instructions (natural history)
Number of subjects: 3
Study: 9226591

Group type: EXPERIMENTAL
Intervention: Rifampicin 1200 mg
Number of subjects: 6
Study: 8095149

Group type: EXPERIMENTAL
Intervention: 10 mg noberastine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg noberastine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg noberastine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3481038

Group type: COMPARATOR
Intervention: Conventional intrathecal methotrexate therapy with cranial irradiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate regimen (10 courses of 33,600 mg/m2 over 24 hours, with high-dose leucovorin rescue)
Number of subjects: 36
Study: 29072551

Group type: EXPERIMENTAL
Intervention: REbeL program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 26160254

Group type: EXPERIMENTAL
Intervention: 7000-IU/d vitamin D3 supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24801056

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22127572

Group type: EXPERIMENTAL
Intervention: Motor imagery (MI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (physiotherapy only)
Number of subjects: 12
Study: 20889945

Group type: EXPERIMENTAL
Intervention: 5 IU bolus of oxytocin
Number of subjects: 143

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 143
Study: 18518727

Group type: EXPERIMENTAL
Intervention: Lumboventricular lavage and simultaneous low-frequency head-motion therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 40
Study: 16377101

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 415
Study: 12784319

Group type: EXPERIMENTAL
Intervention: 800 mg albendazole daily for 15 days
Number of subjects: 12
Study: 11022182

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8
Study: 8630634

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg once daily
Number of subjects: 255

Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 255
Study: 1486669

Group type: EXPERIMENTAL
Intervention: Vitamin A 30,000 RE (100,000 IU)
Number of subjects: 2840

Group type: EXPERIMENTAL
Intervention: Vitamin A 15,000 RE (50,000 IU)
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Placebo (75 RE (250 IU) and 150 RE (500 IU))
Number of subjects: 2840
Study: 6437268

Group type: COMPARATOR
Intervention: Intramuscular piritramide
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural with 0.125% bupivacaine
Number of subjects: 35
Study: 31146579

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive dental intervention
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study: 30589005

Group type: COMPARATOR
Intervention: Sodium fluoride mouthrinse (0.05%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tulsi mouthrinse (4%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Black myrobalans mouthrinse (2.5%)
Number of subjects: 60
Study: 26481918

Group type: EXPERIMENTAL
Intervention: Oral propranolol at a dose of 2 mg/kg per day in three divided doses
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral ibuprofen at a dose of 10 mg/kg 8-hourly and paracetamol at a dose of 16.2 mg/kg 8-hourly
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 23688125

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 273
Study: 22507978

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: pravastatin 20 mg/day
Number of subjects: 50
Study: 19835669

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (drug-free depressed patients)
Number of subjects: 44
Study: 17490962

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (6 g tuna FO/d, approximately 1.9 g n-3 FA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (walking 3 d/wk for 45 min at 75% age-predicted maximal heart rate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) and exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunflower oil (SO; control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunflower oil and exercise (SOX)
Number of subjects: 0
Study: 15716684

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake
Number of subjects: 25
Study: 12652153

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 89
Study: 10366081

Group type: EXPERIMENTAL
Intervention: Citicoline (Neuroton, 1000 mg/day intramuscularly for 60 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (physiologic solution with additives for 60 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Citicoline (second 60-day treatment) in GC2 patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Citicoline (after washout in GC1 patients)
Number of subjects: 40
Study: 7718376

Group type: EXPERIMENTAL
Intervention: 0.75% isoflurane in oxygen for 8 min
Number of subjects: 7

Group type: COMPARATOR
Intervention: 100% oxygen for 8 min
Number of subjects: 7
Study: 1935341

Group type: EXPERIMENTAL
Intervention: Visual recognition (V-V)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tactual recognition (T-T)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: T-V transfer
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: V-T transfer
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramodal transfer
Number of subjects: 36
Study: 7138954

Group type: EXPERIMENTAL
Intervention: Theta feedback
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SMR feedback
Number of subjects: 16
Study: 31609426

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 29938411

Group type: EXPERIMENTAL
Intervention: Copal varnish
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dentin adhesive liner
Number of subjects: 60
Study: 26562568

Group type: EXPERIMENTAL
Intervention: Tennis Ball Technique (TBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsupine Positioning (NSP) regimen without TBT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tennis Ball Technique (TBT) for noncompliant participants
Number of subjects: 40
Study: 24381332

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2‐0.7 µg/kg/h after a loading dose of 1 µg/kg with 1.2‐2.4 µg/kg/h of remifentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midazolam (1‐2 mg) with 3.6‐7.2 µg/kg/h of remifentanil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil
Number of subjects: 90
Study: 21621471

Group type: EXPERIMENTAL
Intervention: Placebo‐loaded Diskus (supervised and assisted use)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MMSE scores
Number of subjects: 40
Study: 21173411

Group type: EXPERIMENTAL
Intervention: Blinded echinacea pills (10.2 g during the first 24 hours and 5.1 g during each of the next 4 days)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Unblinded echinacea pills (10.2 g during the first 24 hours and 5.1 g during each of the next 4 days)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Blinded placebo pills (indistinguishable from echinacea)
Number of subjects: 719

Group type: COMPARATOR
Intervention: No pills
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Blinded echinacea pills
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Unblinded echinacea pills
Number of subjects: 719

Group type: COMPARATOR
Intervention: Blinded placebo pills
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Open-label echinacea pills
Number of subjects: 719
Study: 18000268

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folic Acid, Calcium, Vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary Fibre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red Meat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low Folate Levels and High Alcohol Consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivitamin and Mineral Supplements
Number of subjects: 0
Study: 15030841

Group type: EXPERIMENTAL
Intervention: Empty-bag technique (EBT) using Healon5
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard injection method using Healon5
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 11211574

Group type: EXPERIMENTAL
Intervention: Chyawanprash (15 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vitamin C (500 mg/d)
Number of subjects: 10
Study: 9580349

Group type: EXPERIMENTAL
Intervention: Videoendoscopic inspection alone
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Vital dye staining (1% methylene blue)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mosaic pattern
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Scalloped folds
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Reduction in the number or loss of duodenal folds
Number of subjects: 167
Study: 7920493

Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening
Number of subjects: 451

Group type: COMPARATOR
Intervention: Symptomatic presentation
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Overall quality of life coefficient for surviving patients
Number of subjects: 451
Study: 2894739

Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg intrathecally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline intrathecally
Number of subjects: 40
Study: 31785463

Group type: COMPARATOR
Intervention: Doxorubicin for 6 cycles (arm A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral trofosfamide (arm B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doxorubicin (arm A)
Number of subjects: 120